MENTOR (2019) — Trial Summary
MENTOR (2019): Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria in patients with membranous nephropathy and was superior in maintaining proteinuria remission at 24 months.
References
- Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46.